S.V. Berestenko, T.A. Novodranova, N.V. Berestenko

Efficacy Formen Combi phytocomplex in the treatment of prostatic hyperplasia in patients with cardiovascular diseases

The studying of the clinical efficiency of Formen Combi phytocomplex in 72 men (the average age was 58,8±7,5 years) with prostatic hyperplasia and cardiovascular diseases was lead. The result of two months of taking the drug was reducing the size of prostatic hyperplasia, residual urine after urination, increase in the concentration of testosterone in the blood. PQ and QT intervals have not increased on an electrocardiogram, which confirms the lack of cardiotoxic effects. Phytocomplex treatment improves blood lipid profile, reduces the concentration of the atherogenic fractions (total cholesterol, low-density lipoproteins and triglycerides), increases the concentration of high density lipoproteins in the examinees. The results obtained suggest usefulness in urology with the taking of this medicine into account the indication in the treatment of the patients with prostatic hyperplasia and the moderate manifestations of the illness, chronic prostatitis and with concomitant cardiovascular diseases. Treatment is well transferred and does not possess any by-effects. The effectiveness of current therapy prostatic hyperplasia Formen Combi phytocomplex in patients with cardiovascular diseases was evident.